Modeling and Simulation Move Downstream

News
Article
Pharmaceutical TechnologyPharmaceutical Technology-03-15-2016
Volume 2016 eBook
Issue 1
Pages: s22-s25

This article explores two commercial platforms, and touches on a new program underway in the UK.

Today, some of the most advanced computer-based models are being used for early research.  However, the move to continuous processing has stimulated interest in process optimization and control. This article explores two commercial platforms, and touches on a new program underway in the UK.

Read this article

from Pharmaceutical Technology’s 2016 Solid Dosage Drug Development and Manufacturing eBook.

View other articles in the

2016 Solid Dosage Drug Development and Manufacturing eBook.
Articles in this issue
Meeting USP Guidelines for Elemental Impurity Analysis with X-ray Fluorescence Spectrometry
Meeting USP Guidelines for Elemental Impurity Analysis with X-ray Fluorescence Spectrometry
Optimizing Tablet Compression
Optimizing Tablet Compression
Excipient-Quality-and-Selection.jpg
Excipient Quality and Selection
Pages-from-PTeBook0316_034-038_continuous_freeman.jpg
Filling the Analysis Gap in the Move to Continuous Processing
Pages-from-PTeBook0316_046-054_Generics_DMFs_Subburaj.jpg
Regulatory Considerations for Controlling Intermediates in Type-II Drug Master Files for the Manufacture of Generic Drug Substances
Pages-from-PTEBook0316_022-025_Modeling.jpg
Modeling and Simulation Move Downstream
Unifying-Excipient-Databases.jpg
Unifying Excipient Databases
Pages-from-PTeBook0316_020-021_Capsugel.jpg
Establishing a New Performance Standard for HPMC Capsules
Recent Videos
Drug Digest: Strategic Partnerships
Michelle Bridenbaker from Unbiased Science discusses her thoughts on the key industry from 2024 and those she anticipates will impact the industry in 2025 and beyond.
Tore Bergsteiner from MAIN5 details his predictions for how the mega trends will shape the bio/pharma industry in 2025 and beyond.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Related Content
TOP NEWS on grunge world map | Image Credit: © Sean K - © Sean K - stock.adobe.com

FDA CBER Director Peter Marks Resigns

Susan Haigney
March 31st 2025
Article

Marks called out an ‘assault’ on truth and science in his resignation letter, which has sent the bio/pharmaceutical industry reeling.

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Sherwin-Williams to Showcase Next-Gen Coatings for Pharma Cleanrooms at INTERPHEX 2025

Feliza Mirasol
March 28th 2025
Article

Sherwin-Williams’ advanced coating systems are designed to ensure safety, sterility, and efficiency in pharma manufacturing environments.

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
April 30th 2024
Podcast

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

TOP NEWS on grunge world map | Image Credit: © Sean K - stock.adobe.com

BIO Survey: Tariffs May Reduce Access, Delay Innovation, Create Red Tape

Patrick Lavery
March 27th 2025
Article

The Biotechnology Innovation Organization’s new membership survey said that 90% of US biotech companies rely on imported components for at least half of their FDA-approved products.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Novartis’ Steady Investments in Slovenia Result in New Viral Vector Manufacturing Facility and a Growing Work Force

Feliza Mirasol
March 27th 2025
Article

With a completed €40 million (US$43 million) investment in Slovenia, Novartis has opened its first specialized viral vector production facility in Europe, following earlier significant investments in R&D that has led to the growth of Slovenia’s workforce.